The deal will see Sanofi acquire all outstanding common shares of US-based Vigil for $8 per share in cash at closing. Virgil’s shares closed at $2.31 on 21 May, meaning Sanofi is paying a ...

Vigil Neuroscience, Inc. has announced a definitive merger agreement with Sanofi, under which Vigil's shareholders will receive up to $10.00 per share in cash, comprising $8.00 at closing and a ...

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer’s disease to the French pharmaceutical company ...

Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of ...

Sanofi is taking on Vigil’s TREM2-targeting drug after other companies have fallen short in their efforts to drug the target. In 2023, Denali Therapeutics and Takeda Pharmaceutical discontinued ...

Sanofi will acquire Vigil Neuroscience , a clinical-stage biotech company in a $470 million deal, the companies said on Thursday, as the French drugmaker seeks to boost its neurological pipeline ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. With the biotech into the final year of its cash runway, Sanofi has swept in to secure a small molecule ...

--Vigil Neuroscience, Inc., a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases and Sanofi, today announced that ...

- Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following ...

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline . Paris, May 22, 2025.

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline . Paris, May 22, 2025.